|
LANCL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.76769998638804E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.24100000054028E-07 |
| Normal-vs-Stage2 |
1.245890E-04 |
| Normal-vs-Stage3 |
6.49830000920559E-09 |
| Normal-vs-Stage4 |
1.12119999950977E-08 |
| Stage1-vs-Stage2 |
8.928800E-01 |
| Stage1-vs-Stage3 |
1.363360E-01 |
| Stage1-vs-Stage4 |
8.209800E-02 |
| Stage2-vs-Stage3 |
2.561400E-01 |
| Stage2-vs-Stage4 |
1.279200E-01 |
| Stage3-vs-Stage4 |
5.680800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.67059999167662E-09 |
| Normal-vs-AfricanAmerican |
3.037500E-03 |
| Normal-vs-Asian |
3.94589999996864E-06 |
| Caucasian-vs-AfricanAmerican |
3.604000E-01 |
| Caucasian-vs-Asian |
9.889600E-01 |
| AfricanAmerican-vs-Asian |
4.007600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.49239995309125E-09 |
| Normal-vs-Female |
2.06079999731656E-08 |
| Male-vs-Female |
1.869620E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.62380000024687E-07 |
| Normal-vs-Age(41-60Yrs) |
1.64519997625234E-09 |
| Normal-vs-Age(61-80Yrs) |
2.74220000040515E-07 |
| Normal-vs-Age(81-100Yrs) |
1.517580E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.477420E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.152200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.985200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.593000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.386400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.900200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.800960E-01 |
| Classical-VS-Follicular |
5.993800E-01 |
| Classical-VS-Other |
4.702400E-01 |
| Classical-VS-Normal |
4.96469999555771E-08 |
| Tall-VS-Follicular |
3.720000E-01 |
| Tall-VS-Other |
9.707200E-01 |
| Tall-VS-Normal |
2.64059999999233E-06 |
| Follicular-VS-Other |
6.636800E-01 |
| Follicular-VS-Normal |
1.6270599999979E-05 |
| Other-VS-Normal |
8.456400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.51470002996268E-09 |
| Normal-vs-N1 |
4.81059999613009E-08 |
| N0-vs-N1 |
1.867960E-01 |
|
|
